Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Shreya Lotia, Shanaya Patel, Aditi Patel, Vaishnavi Patel, Kanisha Shah, Vivek Tanavde
Format: Artículo Open Access
Veröffentlicht: Wiley 2024
Schlagworte:
Online-Zugang:https://onlinelibrary.wiley.com/doi/10.1002/ptr.8150
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1867009701876596736
author Shreya Lotia
Shanaya Patel
Aditi Patel
Vaishnavi Patel
Kanisha Shah
Vivek Tanavde
author_facet Shreya Lotia
Shanaya Patel
Aditi Patel
Vaishnavi Patel
Kanisha Shah
Vivek Tanavde
Shreya Lotia
Shanaya Patel
Aditi Patel
Vaishnavi Patel
Kanisha Shah
Vivek Tanavde
collection Wiley Open Access
contents Unravelling the role of Silibinin in targeting CD44+ cancer stem cells: Therapeutic implications, effective strategies and approaches Shreya Lotia Shanaya Patel Aditi Patel Vaishnavi Patel Kanisha Shah Vivek Tanavde Phytotherapy Research AbstractCD44+ cancer stem cells (CSCs) are believed to account for drug resistance and tumour recurrence due to their potential to self‐renew and differentiate into heterogeneous lineages. Therefore, efficient treatment strategies targeting and eliminating these CSCs are required. The flavonolignan, Silibinin, has gained immense attention in targeting CD44+ CSCs as it alters functional properties like cell cycle arrest, apoptosis, inhibition of invasion and metastasis and also inhibits a range of molecular pathways. However, its limited bioavailability is a major hurdle in asserting Silibinin as a translational therapeutic agent. Combinatorial therapy of Silibinin with conventional chemotherapeutic drugs is an alternative approach in targeting CD44+ CSCs as it increases the efficacy and reduces the cytotoxicity of chemotherapeutic drugs, thus preventing drug resistance. Certain Silibinin‐conjugated nano‐formulations have also been successfully developed, through which there is improved absorptivity/bioavailability of Silibinin and a decrease in the concentration of therapeutic drugs leading to reduced cytotoxicity. In this review, we summarise the effectiveness of the synergistic therapeutic approach for Silibinin in targeting the molecular mechanisms of CD44+ CSCs and emphasise the potential role of Silibinin as a novel therapeutic agent. 10.1002/ptr.8150 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/ptr.8150
format Artículo Open Access
id wiley_oa_10_1002_ptr_8150
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Unravelling the role of Silibinin in targeting CD44+ cancer stem cells: Therapeutic implications, effective strategies and approaches
Shreya Lotia
Shanaya Patel
Aditi Patel
Vaishnavi Patel
Kanisha Shah
Vivek Tanavde
Phytotherapy Research
Unravelling the role of Silibinin in targeting CD44+ cancer stem cells: Therapeutic implications, effective strategies and approaches Shreya Lotia Shanaya Patel Aditi Patel Vaishnavi Patel Kanisha Shah Vivek Tanavde Phytotherapy Research AbstractCD44+ cancer stem cells (CSCs) are believed to account for drug resistance and tumour recurrence due to their potential to self‐renew and differentiate into heterogeneous lineages. Therefore, efficient treatment strategies targeting and eliminating these CSCs are required. The flavonolignan, Silibinin, has gained immense attention in targeting CD44+ CSCs as it alters functional properties like cell cycle arrest, apoptosis, inhibition of invasion and metastasis and also inhibits a range of molecular pathways. However, its limited bioavailability is a major hurdle in asserting Silibinin as a translational therapeutic agent. Combinatorial therapy of Silibinin with conventional chemotherapeutic drugs is an alternative approach in targeting CD44+ CSCs as it increases the efficacy and reduces the cytotoxicity of chemotherapeutic drugs, thus preventing drug resistance. Certain Silibinin‐conjugated nano‐formulations have also been successfully developed, through which there is improved absorptivity/bioavailability of Silibinin and a decrease in the concentration of therapeutic drugs leading to reduced cytotoxicity. In this review, we summarise the effectiveness of the synergistic therapeutic approach for Silibinin in targeting the molecular mechanisms of CD44+ CSCs and emphasise the potential role of Silibinin as a novel therapeutic agent. 10.1002/ptr.8150 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Unravelling the role of Silibinin in targeting CD44+ cancer stem cells: Therapeutic implications, effective strategies and approaches
topic Phytotherapy Research
url https://onlinelibrary.wiley.com/doi/10.1002/ptr.8150